

The effect of focused extracorporeal shock wave therapy on collagen matrix and gene expression in normal tendons and ligaments

G. BOSCH*, M. DE MOS†, R. VAN BINSBERGEN, H. T. M. VAN SCHIE†, C. H. A. VAN DE LEST‡ and P. R. VAN WEEREN

Department of Equine Sciences, Faculty of Veterinary Medicine, Utrecht University, Yalelaan 12, 3584 CM Utrecht; †Erasmus MC University Medical Center, Department of Orthopaedics, Rotterdam; and ‡Department of Biochemistry and Cell Biology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Keywords: horse; tendon; shock wave; collagen; histology; gene expression

Materials and methods

Experimental set-up

The ponies were sedated with detomidine¹ (Domosedan, 0.01 mg/kg bwt i.v.) and butorphanol tartrate (Torbugesic, 0.1 mg/kg bwt i.v.)². Extracorporeal shock waves were generated electro-hydraulically using an Equitron device³. In one weightbearing front limb ESWT was applied to the mid-metacarpal region of the superficial digital flexor tendon (SDFT) over an area of 5 cm and to the origin of the suspensory ligament (SL), which was accessed from the lateral side. Using a probe with the focal point at 5 mm, 600 shocks were applied to both sites, at an energy level of E6, giving an energy flux density (EFD) of 0.14 mJ/mm². The other front limb was left untreated.

After 6 weeks, ESWT was applied to the same limbs, using an identical protocol, but now at the mid-metacarpal region of the common digital extensor tendon (ET) and at the insertion on the extensor process of the 3rd phalanx of this tendon (EP). To access the EP the probe was placed dorsally just above the coronary band, perpendicular to the skin. Three hours after the last treatment the animals were subjected to euthanasia using an overdose (200 mg/kg bwt i.v.) of Pentobarbital (Euthesate)⁴ after sedation with 0.01 mg/kg bwt detomidine.

Samples were obtained from all treated and contralateral untreated control tendons directly after euthanasia. Specimens were taken from the core region of the tendons and the samples were divided for different analyses (histology, biochemistry, gene expression).

Collagen content, hydroxylysine and cross links

After lyophilising for 24 h, approximately 1 mg tendon sample was hydrolysed (110°C, 18–20 h) in 6 mol/l HCl for mass

spectrometric (MS) determination of the amino acids hydroxyproline (Hyp) and hydroxylysine (Hyl), and the enzymatic collagen cross links hydroxylsilypyridinoline (HP) and lysylpyridinoline (LP).

The hydrolysed tendon samples were vacuum-dried and dissolved in an internal standard solution (2.4 mmol/l homo-arginine). After centrifugation at 13,000 *g* for 20 min, the supernatants were subjected to HPLC/MS.

HPLC/MS analysis was performed using a 4000 Q-TRAP mass-spectrometer⁵ equipped with an electrospray ion source in positive-mode. MS was performed at a source temperature of 400°C, and a spray voltage of 4.5 kV. Amino acids were separated on a Synergi MAX-RP 80A (250 x 3 mm, 4 µm) column⁶ at a flow rate of 200 µl/min, using a linear gradient from MilliQ water to acetonitrile. Both eluents contained 1.2 mmol/l tridecafluoroheptanoic acid as an ion pairing substance. The amino acids were further analysed and identified by mass-spectrometer in MRM mode using the following transitions 429.0/82.0, 413.0/84.0, 189.2/143.7, 131.8/67.8 and 163.2/127.9 (Mz) for HP, LP, homo-arginine, Hyp and Hyl, respectively.

Degraded collagen

The assay for degraded collagen is based on the observation that α-chymotrypsin (αCT) digests denatured collagen but not the intact triple helix (Bank *et al.* 1997).

The tendon samples were homogenised using a Mikro-Dismembrator⁷. Homogenates were extracted with 1 ml 4 mmol/l guanidine-HCl to remove proteoglycans. After removal of the guanidine-HCl, the denatured collagen was digested overnight at 37°C using 0.25 mg of αCT. After treatment with αCT, the digested collagen containing supernatant was separated from the remaining insoluble matrix, containing the intact collagen.

TABLE 01: Oligonucleotide primer sequences for polymerase chain reaction (PCR) assays

Target	Forward primer	Reverse primer
COL1	TGCCATCAAAGTCTTCTGCAA	CGCCATACTCGAACTGGAATC
COL3	TACTTCTCGCTCTGCTTCATCC	GAACGGATCCTGAGTCACAGA
MMP3	TTTTGGCCATCTCTTCTTCA	TGTGGATGCCTCTTGGGTATC
MMP13	CAAGGGATCCAGTCTCTCTATGGT	GGATAAGGAAGGGTCACATTTGTC
MMP14	GGACTGTCCGGAATGAGGATCT	TTGGAATGCTCAAGGCCCA
GAPDH	GTCAACGGATTGGTCGTATTGGG	TGCCATGGGTGGAATCATATTGG

Collagen contents in both supernatant and pellet were determined by measuring hydroxyproline levels as described before (Creemers *et al.* 1997). The concentration of degraded collagen was calculated as follows: $\text{Hyp}_{\text{supernatant}} / (\text{Hyp}_{\text{supernatant}} + \text{Hyp}_{\text{pellet}}) \times 100\%$ (Bank *et al.* 1997).

Gene expression

For gene expression, tissue was snap frozen in liquid nitrogen and stored at -80°C until further analysis. Expression levels of genes COL1 and COL3 and for MMP3, MMP13 and MMP14, as well as for the household gene GAPDH were determined, using real-time RT-PCR.

Homogenised tendon specimens were suspended in 1.8 ml/100 mg RNA-Bee⁸. RNA was isolated over RNeasy purification columns⁹ and samples were treated with DNase to degrade any DNA residues. One μg total RNA was reverse-transcribed into cDNA using a RevertAid First Strand cDNA Synthesis Kit¹⁰, according to the manufacturer's guidelines. Primers were designed to bind to separate exons to avoid co-amplification of genomic DNA and to meet SYBRGreen I¹¹ requirements, using PrimerExpress 2.0 software¹². BLASTn searches were conducted to ensure gene specificity of all primers listed in Table 1. Amplification was performed in 20 μl reactions using qPCR Mastermix Plus for SYBRGreen I according to the manufacturer's guidelines. Real-time RT-PCR (QPCR) was performed using an ABI PRISM 7000 with SDS software version 1.7. Data were

normalised to the household gene GAPDH, which was shown to be stably expressed across samples. Relative expression was calculated according to the $2^{-\Delta\text{CT}}$ formula (Livak and Schmittgen 2001).

Manufacturers' addresses

¹Orion Pharma, Espoo, Finland.

²Fort Dodge Animal Health, Ft. Dodge, Iowa, USA.

³High Medical Technologies, Lengwil, Switzerland.

⁴Ceva Sante Animale, Naaldwijk, The Netherlands.

⁵Applied Biosystems/MDS Sciex, Concord, Ontario, Canada.

⁶Phenomenex Inc, Torrance, California, USA.

⁷BioTech International Inc, Needville, Texas.

⁸TEL-TEST, Friendswood, Texas, USA.

⁹Qiagen, Hilden, Germany.

¹⁰MBI Fermentas, St. Leon-Rot, Germany.

¹¹Eurogentec Nederland B.V., Maastricht, The Netherlands.

¹²Applied Biosystems, Foster City, California, USA.

References

- Bank, R.A., Krikken, M., Beekman, B., Stoop, R., Maroudas, A., Lafeber, F.P. and te Koppele, J.M. (1997) A simplified measurement of degraded collagen in tissues: application in healthy, fibrillated and osteoarthritic cartilage. *Matrix Biol.* **16**, 233-243.
- Creemers, L.B., Jansen, D.C., van Veen-Reurings, A., van den Bos, T. and Everts, V. (1997) Microassay for the assessment of low levels of hydroxyproline. *Biotechniques* **22**, 656-658.
- Livak, K.J. and Schmittgen, T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-(\Delta\Delta\text{C(T)})}$ method. *Methods* **25**, 402-408.